Comprehensive, easy-to-understand information about this condition
How we create this content →Documentation for pulmonary systemic sclerosis is limited due to its rarity and the complexity of its clinical features, which can overlap with other conditions. The low prevalence means fewer systematic studies have been conducted, making it challenging to establish a comprehensive understanding of the disease. This can be frustrating for patients seeking clarity and guidance.
To navigate your care effectively, consider seeking a pulmonologist with expertise in systemic sclerosis and related lung diseases. It may also be beneficial to connect with a clinical trial coordinator to explore participation in ongoing studies that could provide access to new treatments. For additional resources, visit the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov, which offers information on rare conditions and potential support avenues.
There is ongoing research into pulmonary systemic sclerosis, with 49 active clinical trials currently available. One FDA-approved treatment for this condition is tocilizumab. Additionally, several orphan drugs are designated for development, although specific details about their phases are not provided. For more information on active trials, you can visit ClinicalTrials.gov at https://clinicaltrials.gov/search?cond=pulmonary%20systemic%20sclerosis.
Actionable guidance for navigating care for pulmonary systemic sclerosis
To navigate your care effectively, consider seeking a pulmonologist with expertise in systemic sclerosis and related lung diseases. It may also be beneficial to connect with a clinical trial coordinator to explore participation in ongoing studies that could provide access to new treatments. For additional resources, visit the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov, which offers information on rare conditions and potential support avenues.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Documentation for pulmonary systemic sclerosis is limited due to its rarity and the complexity of its clinical features, which can overlap with other conditions. The low prevalence means fewer systematic studies have been conducted, making it challenging to establish a comprehensive understanding of the disease. This can be frustrating for patients seeking clarity and guidance.
To navigate your care effectively, consider seeking a pulmonologist with expertise in systemic sclerosis and related lung diseases. It may also be beneficial to connect with a clinical trial coordinator to explore participation in ongoing studies that could provide access to new treatments. For additional resources, visit the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov, which offers information on rare conditions and potential support avenues.
There is ongoing research into pulmonary systemic sclerosis, with 49 active clinical trials currently available. One FDA-approved treatment for this condition is tocilizumab. Additionally, several orphan drugs are designated for development, although specific details about their phases are not provided. For more information on active trials, you can visit ClinicalTrials.gov at https://clinicaltrials.gov/search?cond=pulmonary%20systemic%20sclerosis.
Actionable guidance for navigating care for pulmonary systemic sclerosis
To navigate your care effectively, consider seeking a pulmonologist with expertise in systemic sclerosis and related lung diseases. It may also be beneficial to connect with a clinical trial coordinator to explore participation in ongoing studies that could provide access to new treatments. For additional resources, visit the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov, which offers information on rare conditions and potential support avenues.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Documentation for pulmonary systemic sclerosis is limited due to its rarity and the complexity of its clinical features, which can overlap with other conditions. The low prevalence means fewer systematic studies have been conducted, making it challenging to establish a comprehensive understanding of the disease. This can be frustrating for patients seeking clarity and guidance.
To navigate your care effectively, consider seeking a pulmonologist with expertise in systemic sclerosis and related lung diseases. It may also be beneficial to connect with a clinical trial coordinator to explore participation in ongoing studies that could provide access to new treatments. For additional resources, visit the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov, which offers information on rare conditions and potential support avenues.
There is ongoing research into pulmonary systemic sclerosis, with 49 active clinical trials currently available. One FDA-approved treatment for this condition is tocilizumab. Additionally, several orphan drugs are designated for development, although specific details about their phases are not provided. For more information on active trials, you can visit ClinicalTrials.gov at https://clinicaltrials.gov/search?cond=pulmonary%20systemic%20sclerosis.
Actionable guidance for navigating care for pulmonary systemic sclerosis
To navigate your care effectively, consider seeking a pulmonologist with expertise in systemic sclerosis and related lung diseases. It may also be beneficial to connect with a clinical trial coordinator to explore participation in ongoing studies that could provide access to new treatments. For additional resources, visit the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov, which offers information on rare conditions and potential support avenues.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
Consider asking your healthcare providers these condition-specific questions
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Organizations with approved therapies for this disease
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.
AI-curated news mentioning pulmonary systemic sclerosis
Updated Feb 9, 2026
Recent research indicates that targeting the PD-1 pathway may reduce inflammation and fibrosis in systemic sclerosis. This discovery could lead to new therapeutic strategies for managing this challenging condition.
A recent retrospective cohort study investigates the impact of hydroxychloroquine on mortality and cardiovascular outcomes in systemic sclerosis. The findings contribute to understanding treatment efficacy in this rare disease.